KaloBios Pharmaceuticals Inc (NASDAQ:KBIO), a monoclonal antibody company focused on developing innovative therapies to benefit patients with diseases of unmet medical need, with a …
KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) today announced the appointment of Ronald A. Martell, to the position of Executive Chairman.
KaloBios Pharmaceuticals Inc (Nasdaq:KBIO) reported its financial results for the first quarter of 2015. Net loss for the quarter ended March 31, 2015 was $9.
KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) announced that it will present at the 14th Annual Needham Healthcare Conference in New York City, New York on April 14, 2015. Herb Cross, Interim Chief Executive Officer …
KaloBios Pharmaceuticals Inc (NASDAQ: KBIO) reported its financial results for the fiscal year 2014. Net loss for the fiscal year ended December 31, …
KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) today announced that David W.
In a research report sent to investors today, Needham analyst Alan Carr reiterated a Hold rating on KaloBios Pharmaceuticals (NASDAQ:KBIO), as the company yesterday …
After the markets closed Monday,July 28, KaloBios Pharmaceuticals (KBIO) announced anagreement with Sanofi (SNY), which returns all rights to the KB001-A program. In addition, KaloBios …
